

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Makoto YOSHIMOTO et al.

Confirmation No. 5398

Group Art Unit:

1632

Appl. No.

: 10/577,302 (National Stage of PCT/JP2004/016373)

Examiner: not yet assigned

I. A. Filed

: October 28, 2004

For

: TRANSGENIC NON-HUMAN MAMMAL

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

Pursuant to 37 C.F.R. § 1.56 and 37 C.F.R. §§ 1.97-1.98, Applicants hereby direct the Examiner's attention to the following documents cited in the specification and International Search Report for International Application PCT/JP2004/016373 of which the above-referenced application is the U.S. National Stage Application. Copies of the International Search Report (in English and Japanese) were enclosed with the papers when entering the National Stage on April 28, 2006:

- (1) Neurobiol. Dis., 2001, 8(3), pp.535-539;
- (2) JP 2003-199460 A; accompanied by an English language abstract provided by esp@cenet;
- (3) WO 01/60794 A2, August 15, 2002; Applicants note that this document is also discussed in the present application, beginning at page 2, line 11;

P29879.A03

- (4) U.S. Patent Application Publication No. 2004/0128706, which is a family member of item (3);
- (5) U.S. Patent Application Publication No. 2002/0111321 (Klein et al.), August 15, 2002;
- (6) U.S. Patent Application Publication No. 2004/0205833, which is a family member of item (5);
- (7) WO 98/59050 A1, December 30, 1998, Applicants note that this document is also discussed in the present application, beginning at page 2, line 11;
- (8) J. Neurosci., 2000, 20(16), pp. 6021-6029;
- (9) Science, 2000, 287 (5456), pp. 1265-1269;
- (10) Exp. Neurol., 2002, 175(1), pp. 35-48;
- (11) Proc. Natl. Acad. Sci. USA, 2003, 100(5), pp. 2884-2889;
- (12) Proc. Natl. Acad. Sci. USA, 2002, 99(16), pp. 10813-10818;
- (13) Brain Res., 2002, 926 (1-2), pp. 42-50;
- (14) Neuroscience, 2000, 97(2), pp.279-284;
- (15) J. Biol. Chem., 2002, 277(32), pp. 28512-28520;
- (16) Biochemistry, 2002, 41(46), pp. 13782-13790;
- (17) Bulletin of the Japanese Society for Neurochemistry, 10 August 2004, 43(2,3) p. 369,0G1-06;
- (18) Neurobiol. Dis., 2004 November, 17(2), p.123-30; and
- (19) K. Kobayashi et al., Proceedings of the National Academy of Sciences USA, Vol. 89, pp.1631-1635, cited in the specification beginning on page 19, line 3.

Applicants note that items, 1, 10, 13, 14, 16-18 were cited in the International Search Report, accordingly copies of these documents should have been forwarded by the International Bureau. Therefore, copies of these documents are not being submitted herewith. The Examiner is accordingly requested to consider each of these documents, and to make them of record in this application by initialing in the appropriate spaces on the attached Form-1449. Applicants respectfully requests that the Examiner include a copy of the initialed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office. If the Examiner needs additional copies of any of the documents, the Examiner is requested to contact the undersigned.

In accordance with 37 C.F.R. § 1.98 and the waiver thereto, a copy of the U.S. published patent application is not enclosed herewith. However, if a copy is needed, the Examiner is respectfully requested to contact the undersigned.

Copies of above listed documents (except for documents 1, 4, 5, 6, 10, 13, 14, and 16-18), the Written Opinion and International Preliminary Report on Patentability (in English) for International Application PCT/JP2004/016373 are enclosed together with a duly completed Form PTO-1449.

The Examiner is accordingly requested to consider each of these documents, and to make them of record in this application by initialing in the appropriate spaces on the Form PTO-1449. Applicants respectfully request that the Examiner include a copy of the initialed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office.

Applicants note that while this Supplemental Information Disclosure Statement is being filed more than three months from the filing date, Applicants have not received an action on the merits from the U.S. Patent and Trademark Office. Accordingly, consideration of the enclosed documents are required under 37 C.F.R. 1.97(b)(3).

P29879.A03

However, if an action on the merits has been mailed prior to the filing date of this Supplemental Information Disclosure Statement, Applicants hereby authorize the charging of any required fees necessary for consideration of the documents cited herein to Deposit Account No. 19-0089.

Any comments or questions concerning this application can be directed to the undersigned at the telephone number given below.

Respectfully submitted, Makoto YOSHIMOTO et al

Can. Ma. a.

Bruce H. Bernstein

Reg. No. 29,027

April 19, 2007 GREENBLUM & BERNSTEIN, P.L.C. 1950 Roland Clarke Place Reston, VA 20191 (703) 716-1191

FORM PTO-1449			U.S. Department of Commerce Patent and Trademark Office			Atty. Docl P29879	ket No.		Application No. 10/577,302			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Makoto YOS								SHIMOTO et al.				
BY APPLICANT (Use several sheets in the cessery)						Filing Date Group						
(Ross)					October 28, 2004				1632			
		API	9 2 4 200	U.S. PATEN	T DOCUMI	ENTS			L	•		
EXAMINER	T		<u>.</u>	R)							DATE	
INITIAL		DOCUMENT	BER	DATE	 	NAME	CLASS	SU	BCLASS	IF APPROPRIATE		
000000000000000000000000000000000000000	2004/			opensi i propinski p	MASLI			000000000000				
	2002/		2 +	08/15/02	 	KLERV et al.						
	2004/	0 2 0 5 8		10/14/04	KLEIN	KLEDLet al.				000000000000000000000000000000000000000	000000000000000000000000000000000000000	
FOREIGN PATENT DOCUMENTS												
		DOCUMENT NUM	4DED	DATE	COL	CLASS	CLID	TRANSLATION SUBCLASS YES N				
	2002	1 0 0 4	6 0	07/15/02	JAPAN	 -		SUBCLASS		163	NO	
		000000000000000000000000000000000000000			W.H.D.O							
	+	, , ,					000000000000000000000000000000000000000	000000000000000	-			
***************************************	98/			12/30/98	WIPO	000000000000000000000000000000000000000		000000000000000000000000000000000000000		000000000000000000000000000000000000000		
					ļ <u>-</u> -							
	ļ <u>-</u>											
	<u> </u>											
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)											
1 Neurobiol. Dis., 2001, 8(3), pp.535-539												
000000000000000000000000000000000000000		J. Neurosci., 2000, 20(16), pp. 6021-6029.										
000000000000000000000000000000000000000	000000000000000000000000000000000000000	Science, 2000, 287 (5456), pp. 1265-1269										
	4	Exp. Neurol. 2002, 175(1), pp. 35-48										
000000000000000000000000000000000000000	5	Proc. Natl. Acad. Sci. USA, 2003, 100(5), pp. 2884-2889.										
000000000000000000000000000000000000000	6	Proc Natl Acad Sci USA, 2002, 99(16), pp. 10813-10818										
	7	Brain Res., 2002, 926 (1-2), pp. 43-50.										
		Neuroscience, 2000, 97(2), pp 279-284									000000000000000000000000000000000000000	
000000000000000000000000000000000000000		J. Biol. Chem., 2002, 277(32), pp. 28512-28520										
	10	Riochemistry, 2002, 41(46), pp. 13782-13790										
000000000000000000000000000000000000000		Dulletin of the Japanese Society for Neurochemistry, 10 August 2004, 43(2,3) p. 369,001-06.										
300000000000000000000000000000000000000		Neurobiol: Dis., 20					000000000000000000000000000000000000000	000000000000000000000000000000000000000				
/M.W./	13	K. Kobayashi et al.	Proceed	ings of the Na	tional Aca	demy of Sc	iences USA,	Vol. 8	9, pp. 163	1-1635.		
200000000000000000000000000000000000000	14		K. Kobayashi et al., Proceedings of the National Academy of Sciences USA, Vol. 89, pp. 1631-1635. English language Abstract of IP 2003-199460									
	<u> </u>											
	 		,									
EXAMINER	<u> </u>	/Michael Wilson/ (06/	19/2008)		DA	TE CONSIDER	RED 06/	19/200	3			
*EXAMINER		tion considered, whether or	not citation	n is in conformar						nance and not	considered.	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.												